Results 41 to 50 of about 101,068 (248)

High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromsø study

Haematologica, 2011
Background High-sensitivity C-reactive protein is associated with risk of arterial cardiovascular disease but conflicting results have been reported on its role in venous thromboembolic disease.
Erin M. Hald, Sigrid K. Brækkan, Ellisiv B. Mathiesen, Inger Njølstad, Tom Wilsgaard, Jan Brox, John-Bjarne Hansen   +6 more
doaj   +1 more source

Effects of Hyperthyroidism on Venous Thromboembolism: A Mendelian Randomization Study

Journal of Immunology Research, 2022
Objective. Observational studies show the correlation between thyroid dysfunction and risk of venous thromboembolism. However, the causal effects remain uncertain. Our study was conducted to evaluate whether thyroid function and dysfunction were causally
Fushi Han, Chunyang Zhang, Miao Xuan, Zhuangli Xie, Kunming Zhang, Ying Li   +5 more
doaj   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Frontiers in Medicine, 2021
Background: Patients suffering from chronic inflammatory disorders, such as inflammatory bowel disorder, are at higher risk of developing thromboembolism.
Hua Zhang, Xuehong Wang
doaj   +1 more source

AB1458 JAK INHIBITORS AND VENOUS THROMBOEMBOLISM EVENTS - REASSURING DATA FROM A LARGE SINGLE CENTRE RETROSPECTIVE STUDY [PDF]

, 2022
Colin Beevor, S. Bartosz-Bowden, M. Fletcher, L. Goh, G. Dulay   +4 more
openalex   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Reliability and validity of Risk Assessment Scale for Perinatal Venous Thromboembolism in parturients

Huli yanjiu, 2022
ObjectiveTo test reliability and validity of Risk Assessment Scale for Perinatal Venous Thromboembolism in parturients.Methods230 parturients who were hospitalized in obstetric ward of the International Peace Maternity and Child Health Hospital，School of
ZHAN Zhuang, GONG Wenyan
doaj  

Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients [PDF]

, 2021
Hilde Skuterud Wik, Susan R. Kahn, Henry Eriksson, David Morrison, Waleed Ghanima, Sam Schulman, Per Morten Sandset   +6 more
openalex   +1 more source

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, EarlyView.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

A real‐world data‐driven approach to optimizing enoxaparin dosing in burn patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation‐based (EQ) dosing and propose an optimized dosing ...
Babajide Shenkoya, Venkata Yellepeddi, Ann Marie B. Prazak, Mathangi Gopalakrishnan   +3 more
wiley   +1 more source